RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Keilty, Dana, Buchanan, Marguerite, Ntapolias, Katerina, Aleynikova, Olga, Tu, Dongsheng, Li, Xiao, Shepherd, Lois, Bramwell, Vivien, Basik, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868649/
https://www.ncbi.nlm.nih.gov/pubmed/24367492
http://dx.doi.org/10.1371/journal.pone.0081740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868649/
https://www.ncbi.nlm.nih.gov/pubmed/24367492
http://dx.doi.org/10.1371/journal.pone.0081740

Ejemplares similares